Successful treatment with oseltamivir phosphate in a patient with chronic immune thrombocytopenia positive for anti-GPIb/IX autoantibody

Platelets

Volumn 26, Issue 5, 2015, Pages 495-497

  Shao, Linlin ^a   Wu, Yang ^a   Zhou, Hai ^a   Qin, Ping ^a   Ni, Heyu ^b   Peng, Jun ^a,c   Hou, Ming ^a,c  

^a SHANDONG UNIVERSITY   (China)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c BEIJING HOSPITAL   (China)

Author keywords

Autoimmune thrombocytopenia; Beta galactose; Beta N acetylglucosamine; Oseltamivir; Platelet glycoprotein GPIb IX complex

Indexed keywords

AUTOANTIBODY; BETA GALACTOSE; DANAZOL; DEXAMETHASONE; GALACTOSE; GLYCAN; GLYCOPROTEIN; OSELTAMIVIR; PREDNISONE; RITUXIMAB; THROMBIN RECEPTOR; THROMBIN RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; VINDESINE;

AGED; ARTICLE; CASE REPORT; COMPUTER PROGRAM; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG MEGADOSE; DRUG WITHDRAWAL; ECCHYMOSIS; FEMALE; FLOW CYTOMETER; FLOW CYTOMETRY; FOLLOW UP; HOSPITAL READMISSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LOW DRUG DOSE; MALE; NASOPHARYNGEAL ASPIRATION; PATIENT REFERRAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTE MEMBRANE; TREATMENT DURATION; BLOOD; IMMUNOLOGY; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; TREATMENT OUTCOME;

AGED; AUTOANTIBODIES; HUMANS; MALE; OSELTAMIVIR; PLATELET COUNT; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; TREATMENT OUTCOME;

EID: 84931367841     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2014.948838     Document Type: Article

References (18)

1. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood 2009;113:2386-2393.
2. McMillan R. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production. Hematol Oncol Clin North Am 2009;23:1163-1175.
3. Hou M, Stockelberg D, Kutti J, Wadenvik H. Antibodies against platelet GPIb/IX, GPIIb/IIIa, and other platelet antigens in chronic idiopathic thrombocytopenic purpura. Eur J Haematol 1995;55: 307-314.
4. Peng J, Ma SH, Liu J, Hou Y, Liu XM, Niu T, Xu RR, Guo CS, Wang XM, Cheng YF, et al. Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: A multicenter cohort study. J Thromb haemost 2014;12:497-504.
5. Webster ML, Sayeh E, Crow M, Chen P, Nieswandt B, Freedman J, Ni H. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies. Blood 2006;108:943-946.
6. Zeng Q, Zhu L, Tao L, Bao J, Yang M, Simpson EK, Li C, van der Wal DE, Chen P, Spring CM, et al. Relative efficacy of steroid therapy in immune thrombocytopenia mediated by anti-platelet GPIIbIIIa versus GPIbalpha antibodies. Am J Hematol 2012;87: 206-208.
7. Li J, Callum JL, Lin Y, Zhou Y, Zhu G, Ni H. Severe platelet desialyation in a patient with glycoprotein Ib/IX antibody-mediated immune thrombocytopenia and fatal pulmonary hemorrhage. Haematologica 2014;99:e61-e63.
8. van der wal DE, Zhu G, Li J, Vadasz B, Yougbare I, Lang S, Freedman J, Ni H. Desialylation: A novel platelet clearance mechanism and a potential new therapeutic target in anti-GPIb antibody mediated thrombocytopenia. Blood (ASH Annual Meeting Abstracts) 2012;120:265.
9. van der wal DE, Li J, Zhu G, Vadasz B, Ma L, Yougbare I, Lang S, Freedman J, Ni H. Anti-GPIb antibody induces platelet desialylation: A novel mechanism of Fc-independent immune thrombocytopenia and a potential new diagnosis and therapy against refractory ITP. Journal of the International Society on Thrombosis and Haemostasis 2013;11(Suppl 2):204.
10. Li CY, Yu Q, Ye ZQ, Sun Y, He Q, Li XM, Zhang W, Luo J, Gu X, Zheng X, Wei L. A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivir. Cell Res 2007;17:357-362.
11. Moore ML, Chi MH, Zhou W, Goleniewska K, O'Neal JF, Higginbotham JN, Peebles Jr RS. Cutting Edge: Oseltamivir decreases T cell GM1 expression and inhibits clearance of respiratory syncytial virus: potential role of endogenous sialidase in antiviral immunity. J Immunol 2007;178:2651-2654.
12. Alioglu B, Tasar A, Ozen C, Selver B, Dallar Y. An experience of oseltamivir phosphate (tamiflu) in a pediatric patient with chronic idiopathic thrombocytopenic purpura: A case report. Pathophysiol Haemost Thromb 2010;37:55-58.
13. Hou M, Peng J, Shi Y, Zhang C, Qin P, Zhao C, Ji X, Wang X, Zhang M. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol 2003;70:353-357.
14. Neunert C, Lim W, Crowther M, Cohen A, Solberg Jr L. Crowther MA, American Society of H. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190-4207.
15. Grewal PK, Uchiyama S, Ditto D, Varki N, Le DT, Nizet V, Marth JD. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med 2008;14:648-655.
16. Rumjantseva V, Grewal PK, Wandall HH, Josefsson EC, Sorensen AL, Larson G, Marth JD, Hartwig JH, Hoffmeister KM. Dual roles for hepatic lectin receptors in the clearance of chilled platelets. Nat Med 2009;15:1273-1280.
17. Nieswandt B, Bergmeier W, Rackebrandt K, Gessner JE, Zirngibl H. Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood 2000; 96:2520-2527.
18. Li J, van der Wal DE, Zhu L, Vadasz B, Simpson EK, Li C, Webster ML, Zhu G, Lang S, Chen P, et al. Fc-independent phagocytosis: Implications for IVIG and other therapies in immune-mediated thrombocytopenia. Cardiovasc Hematol Disord Drug Targets 2013; 13:50-58.